Biblio Discovery — Demo Discovery Service

25 hasil untuk "Jake Shortt"

Menampilkan 1–20 · 0,21 detik · RSS

  1. Artikel Jurnal

    Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy

    Thomas P. Toohey; Jake Shortt; Nevin John dkk.

    American Journal of Ophthalmology Case Reports, Vol. 36 · 2024 · Inggris · DOAJ Scopus

    Purpose: To determine the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in the setting of optic disc edema secondary to hematologic malignancies. Observations: The report features two patients (one male, one female) in their 70's with biopsy proven hematologic malignancies…

  2. Artikel Jurnal

    Changes in immune cell populations following KappaMab, lenalidomide and low‐dose dexamethasone treatment in multiple myeloma

    Samuel E Norton; Tiffany Khong; Malarmathy Ramachandran dkk.

    Clinical & Translational Immunology, Vol. 12 No. 12 · 2023 · Inggris · DOAJ Scopus

    Abstract Objectives Lenalidomide (LEN) is used to treat multiple myeloma (MM) and shows in vitro synergy with KappaMab (KM), a chimeric antibody specific for Kappa Myeloma antigen, an antigen exclusively expressed on the surface of kappa‐restricted MM cells. Lenalidomide, dexamethasone (DEX) and KM…

  3. Artikel Jurnal Teks lengkap

    A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

    Jake Shortt; Galettis, Peter; Cheah, Chan Y. dkk.

    Clin Epigenetics · 2023 · Inggris · PubMed Central

    BACKGROUND: N-methyl-2-pyrrolidone (NMP) is an epigenetically active chemical fragment and organic solvent with numerous applications including use as a drug-delivery vehicle. Previously considered biologically inert, NMP demonstrates immunomodulatory and anti-myeloma properties that are partly…

    Juga tersedia di: DOAJ

  4. Artikel Jurnal

    Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse

    Mark Waltham; Jonathan Wong; Galina Polekhina dkk.

    eJHaem, Vol. 6 No. 4 · 2025 · Inggris · DOAJ

    ABSTRACT Background Next generation sequencing (NGS) of cell free tumour DNA (ctDNA) provides a snapshot of lymphoma mutations correlating with tumour burden. We evaluated the ability of ctDNA to molecularly profile and track disease burden in patients with aggressive‐B‐cell lymphoma. Methods…

  5. Artikel Jurnal

    Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough?

    Mark A. Dawson; Sharon Avery; Zoe K. McQuilten dkk.

    Haematologica, Vol. 92 No. 7 · 2007 · Inggris · DOAJ Scopus

    Although essential in the management of AML, there is little information quantitating transfusion requirements for these patients. We evaluated 111 consecutive adults treated for AML, showing that approximately 150 blood donors are required to adequately cater for a single patient’s complete…

  6. Artikel Jurnal

    Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy

    Hiu Lam Agnes Yuen; Alison Slocombe; Vanessa Heron dkk.

    Research and Practice in Thrombosis and Haemostasis, Vol. 4 No. 6 · 2020 · Inggris · DOAJ Scopus

    Abstract Background In primary central nervous system lymphoma (PCNSL), venous thromboembolism (VTE) can cause significant morbidity and hinder chemotherapy delivery. Objectives To assess VTE incidence, timing and adequacy of inpatient and outpatient VTE prophylaxis in patients with PCNSL receiving…

  7. Artikel Jurnal

    Bortezomib-based antibody depletion for refractory autoimmune hematological diseases

    Sumita Ratnasingam; Patricia A. Walker; Huy Tran dkk.

    Blood Advances, Vol. 1 No. 1 · 2016 · Inggris · DOAJ Scopus

    Abstract: Certain patients with antibody-mediated autoimmune disease exhibit poor responses to conventional immunosuppression, including B-cell depletion with rituximab. Proteasome inhibitors such as bortezomib demonstrate pleiotropic immunomodulatory effects, including direct toxicity to…

  8. Artikel Jurnal

    Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus

    Baolong Pan; Simon J. Mountford; Maki Kiso dkk.

    Communications Medicine, Vol. 5 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Effective antiviral therapy is lacking for most viral infections, and when available, is frequently compromised by the selection of resistance. Targeted protein degraders could provide an avenue to more effective antivirals, able to overcome the selection of resistance. The aim…

  9. Artikel Jurnal

    BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

    Simon J. Hogg; Stephin J. Vervoort; Sumit Deswal dkk.

    Cell Reports, Vol. 18 No. 9 · 2017 · Inggris · DOAJ Scopus

    Summary: BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evaluated as anti-cancer agents. We find that maximal therapeutic effects of BETi in a Myc-driven B cell lymphoma model required an intact host immune system. Genome-wide analysis of the BETi-induced…

  10. Artikel Jurnal

    T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial

    Eliza A. Hawkes; Jodie B. Palmer; Richard Khor dkk.

    Blood Advances, Vol. 9 No. 20 · 2025 · Inggris · DOAJ Scopus

    Abstract: Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffective in DLBCL/FL; however, evidence suggests synergy…

  11. Artikel Jurnal

    The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

    Lucy C. Fox; Katherine D. Cummins; Ben Costello dkk.

    Blood Advances, Vol. 1 No. 13 · 2017 · Inggris · DOAJ Scopus

    Abstract: Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) in chronic phase chronic myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural effusions and pulmonary hypertension, and…